Elsevier

Clinical Radiology

Volume 37, Issue 2, January–November 1986, Pages 169-171
Clinical Radiology

Results of intracavitary radium treatment for adenocarcinoma of the body of the uterus

https://doi.org/10.1016/S0009-9260(86)80392-0Get rights and content

Between 1965 and 1970, 160 inoperable patients with adenocarcinoma of the endometrium were treated using intracavitary radium alone. Patients were given either two insertions (7500 cGy stated dose over 10 days), or one insertion (5000 cGy stated dose over 4 days) depending on their general condition. The FIGO stage and histological degree of differentiation had a significant influence on survival. Most patients had Stage 1 disease; 5-year and 10-year corrected survival for those having two insertions was 73% and 62% respectively, compared with 58% and 34% respectively for those having a single insertion (p<0.015). The primary tumour control rate was greater using two insertions (77%) than with a single insertion (67%). Treatment morbidity was low. In this selected group of patients, intracavitary radium using a central intrauterine line source and vaginal ovoids produced results comparable with other reported radiotherapy techniques.

References (13)

  • FayosJ.V. et al.

    Carcinoma of the endometrium, results of treatment

    International Journal of Radiation Oncology, Biology, Physics

    (1980)
  • StricklandP.

    Carcinoma corporis uteri: a radical intracavitary treatment

    Clinical Radiology

    (1965)
  • BadibA.O. et al.

    Evaluation of primary radiation therapy in Stage 1, Group 2, endometrial carcinoma

    Radiology

    (1969)
  • BoronowR.C.

    Staging of endometrial cancer

    International Journal of Radiation Oncology, Biology, Physics

    (1980)
  • ColeM.P. et al.

    Female genital tract

  • Fédération Internationale de Gynécologie et Obstétrique (FIGO)

    Acta Obstetrica et Gynecologica Scandinavica

    (1971)
There are more references available in the full text version of this article.

Cited by (23)

  • High Dose Rate Brachytherapy for Inoperable Endometrial Cancer: a Case Series and Systematic Review of the Literature

    2021, Clinical Oncology
    Citation Excerpt :

    Brachytherapy for the sole management of endometrial carcinoma was first described by Heyman in 1935, prior to the routine use of hysterectomy for uterine cancer [7]. Initially, low dose rate (LDR) brachytherapy with Ra-226 or Cs-137 was carried out [8–20]. Recent advances in gynaecological brachytherapy have shifted the brachytherapy treatment planning from LDR brachytherapy to high dose rate (HDR) brachytherapy [21,22].

  • Image-based intracavitary brachytherapy in the treatment of inoperable uterine cancer: Individual dose specification at specific anatomical sites

    2005, Brachytherapy
    Citation Excerpt :

    Fortunately, 75% of women have Stage I disease at the time of diagnosis. Although a total abdominal hysterectomy with bilateral salpingo-oophorectomy is the standard treatment for organ-confined endometrial cancer, patients with high operative risk due to underlying medical conditions have been treated using intracavitary brachytherapy (ICBT) with or without pelvic external beam treatment (2–4). Although the dose specification of ICBT for cervical cancer was well established as Point A in the early days of radium therapy, there is still no consensus on which standard reference point should be used for endometrial cancer.

  • Analgesia for pelvic brachytherapy

    2002, British Journal of Anaesthesia
    Citation Excerpt :

    The treatment of choice for most patients with endometrial cancer is simple hysterectomy, with cure rates of 80–90% if the tumour is confined to the uterus.1 In patients considered unfit for surgery, intracavity brachytherapy can result in a 5-yr survival of up to 73%.14 Manually inserted radiation sources provide ‘gold standard’ treatment results at the expense of radiation exposure of staff.

View all citing articles on Scopus
View full text